(Q38152756)

29 August 2017

title

Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability (English)

1 reference

29 August 2017

author

Christopher R Chapple

series ordinal

1

1 reference

29 August 2017

3

1 reference

29 August 2017

Martin Christian Michel

series ordinal

5

object named as

Martin C Michel

1 reference

29 August 2017

2

Linda Cardozo

1 reference

29 August 2017

Emad Siddiqui

4

1 reference

29 August 2017

publication date

11 October 2013

1 reference

Neurourology and Urodynamics

29 August 2017

published in

1 reference

29 August 2017

volume

33

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

17-30

1 reference

Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments

29 August 2017

cites work

1 reference

Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment

21 January 2018

1 reference

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

21 January 2018

1 reference

The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis

21 January 2018

1 reference

Muscarinic receptor antagonists for overactive bladder

21 January 2018

1 reference

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience

21 January 2018

1 reference

Urinary bladder contraction and relaxation: physiology and pathophysiology

21 January 2018

1 reference

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate

21 January 2018

1 reference

Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium

21 January 2018

1 reference

Beta3-adrenoceptors in human detrusor muscle

21 January 2018

1 reference

Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man.

21 January 2018

1 reference

Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors

21 January 2018

1 reference

Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function

21 January 2018

1 reference

Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome

21 January 2018

1 reference

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers

21 January 2018

1 reference

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist

21 January 2018

1 reference

Bladder selectivity of the novel β₃-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat.

21 January 2018

1 reference

Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips.

21 January 2018

1 reference

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial

21 January 2018

1 reference

Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder

21 January 2018

1 reference

A phase II dose-ranging study of mirabegron in patients with overactive bladder

21 January 2018

1 reference

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial

21 January 2018

1 reference

Results of a randomized phase III trial of mirabegron in patients with overactive bladder

21 January 2018

1 reference

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

21 January 2018

1 reference

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder

21 January 2018

1 reference

Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.

21 January 2018

1 reference

Determining the importance of change in the overactive bladder questionnaire.

21 January 2018

1 reference

Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction

21 January 2018

1 reference

Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns

21 January 2018

1 reference

Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/NAU.22505

1 reference

29 August 2017

1 reference